Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
US8778962
(Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
US8436010
(Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
US8410131
(Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(3 years from now) | |
US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(3 months from now) |
Market Authorisation Date: 21 December, 2010
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) |
Drugs and Companies using INDACATEROL MALEATE ingredient
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9402805 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(4 months ago) | |
US9149486 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(4 months ago) | |
US9345714 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(4 months ago) | |
US8846650 | NOVARTIS | Method of treating middle ear infections |
Jun, 2025
(2 years from now) |
Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient
Market Authorisation Date: 18 July, 2003
Treatment: Treatment of acute otitis media; Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(3 months from now) | |
US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(3 months from now) | |
US8475839
(Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(9 months from now) |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(3 years from now) | |
US8324283
(Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(3 years from now) | |
US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(4 years from now) | |
US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(4 years from now) | |
US9187405
(Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(4 years from now) | |
US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(9 years from now) | |
US9592208
(Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(9 years from now) |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
Market Authorisation Date: 21 September, 2010
Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6958335
(Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(7 months ago) |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 18 April, 2003
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8158645 | NOVARTIS | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(1 year, 10 months from now) |
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 October, 2007
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7947295 | NOVARTIS | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(1 year, 4 months from now) | |
US9662398 | NOVARTIS | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(7 years from now) | |
US8921337 | NOVARTIS | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(9 years from now) |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(6 years from now) | |
US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(6 years from now) | |
US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(7 years from now) | |
US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(8 years from now) | |
US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; In combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(7 years from now) | |
US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(8 years from now) | |
US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(10 months ago) | |
US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(9 months ago) | |
US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(21 days from now) | |
US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(9 months from now) | |
US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(11 months from now) | |
US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 1 month from now) | |
US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 1 month from now) | |
US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 1 month from now) | |
US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(4 years from now) | |
US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(6 months ago) | |
US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(9 months from now) | |
US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(4 years from now) | |
US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 26, 2024 |
M | Mar 1, 2025 |
Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient
NCE-1 date: March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(4 years from now) | |
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(2 years from now) | |
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
M | Oct 6, 2022 |
New Indication (I) | Jun 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Treatment of unresectable or metastatic melanoma; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9114168 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(6 years from now) | |
US8450311 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(6 years from now) |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071648 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
US8324281 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
US7834059 | NOVARTIS | Topical nepafenac formulations |
Jan, 2027
(4 years from now) |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(4 months ago) | |
US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(3 days from now) | |
US8399508
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(a month from now) | |
US7977376
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(6 months from now) |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
CN102149711B | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
CN102149711A | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
IN307469B | NOVARTIS | The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide) |
Sep, 2029
(6 years from now) | |
EP2331537A1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) | |
EP2331537B1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(2 months ago) | |
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7160870
(Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(3 months from now) | |
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(3 months from now) | |
US7795293
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(9 months from now) | |
US7547719
(Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) | |
US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(4 years from now) | |
US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(4 years from now) | |
US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(4 years from now) | |
US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(4 years from now) | |
US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(4 years from now) | |
US8052994
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(5 years from now) | |
US8828430
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(5 years from now) | |
US8071129
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(5 years from now) | |
US8062665
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(5 years from now) | |
US8052993
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 20 November, 2008
Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(2 months ago) | |
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7160870
(Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(3 months from now) | |
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(3 months from now) | |
US7795293
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(9 months from now) | |
US7547719
(Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(8 months from now) | |
US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) | |
US7932241
(Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(5 years from now) |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(3 months ago) | |
US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(5 years from now) | |
US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(10 years from now) | |
US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 29, 2026 |
Orphan Drug Exclusivity (ODE) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(6 years from now) | |
US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(6 years from now) | |
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(2 years from now) | |
US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(6 years from now) | |
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
M | Oct 6, 2022 |
New Indication (I) | Jun 22, 2025 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; Treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; Tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test; Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Treatment of melanoma; Tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(5 months from now) | |
US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(3 years from now) | |
US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(5 years from now) | |
US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169791
(Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(11 months from now) | |
US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(3 years from now) | |
US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(3 years from now) | |
US8415363
(Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
US8389537
(Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
US8501760
(Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(3 years from now) | |
US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(4 years from now) | |
US8293756
(Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(5 years from now) | |
US8163904
(Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(6 years from now) | |
US9061029
(Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 23, 2028 |
Pediatric Exclusivity (PED) | Sep 22, 2025 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 29 October, 2007
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph + cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(6 years from now) |
Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 26 August, 2010
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8211880 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(6 years from now) | |
US8128960 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(6 years from now) |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(6 years from now) |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
Market Authorisation Date: 13 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months from now) | |
US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months from now) |
Drugs and Companies using TELBIVUDINE ingredient
Market Authorisation Date: 25 October, 2006
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(3 years from now) |
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
Market Authorisation Date: 16 September, 2009
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
CN102149711B | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
CN102149711A | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
IN307469B | NOVARTIS | The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide) |
Sep, 2029
(6 years from now) | |
EP2331537A1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) | |
EP2331537B1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(8 months from now) |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2009
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 9 months from now) | |
US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 9 months from now) | |
US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(2 years from now) | |
US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(3 years from now) | |
US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 9 months from now) | |
US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 9 months from now) | |
US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 9 months from now) | |
US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(3 years from now) | |
US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(6 years from now) | |
US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(6 years from now) | |
US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(6 years from now) | |
US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(7 years from now) | |
US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(10 years from now) | |
US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(10 years from now) |
Drugs and Companies using LIFITEGRAST ingredient
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(2 years from now) | |
US8324189
(Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(2 years from now) | |
US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(a day from now) | |
US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(a day from now) | |
US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(a day from now) | |
US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(a day from now) | |
US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(3 years from now) | |
US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(5 years from now) | |
US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(7 years from now) | |
US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
Market Authorisation Date: 29 April, 2014
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic